Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism

Jillian Davidson, D Rotondo, Maria Rizzo, Anne Leaver

Research output: Contribution to journalLiterature review

25 Citations (Scopus)

Abstract

Disruptions of cell death signalling occur in pathological processes, such as cancer and degenerative disease. Increased knowledge of cell death signalling has opened new areas of therapeutic research, and identifying key mediators of cell death has become increasingly important. Early triggering events in cell death may provide potential therapeutic targets, whereas agents affecting later signals may be more palliative in nature. A group of primary mediators are derivatives of the highly unsaturated fatty acids (HUFAs), particularly oxygenated metabolites such as prostaglandins. HUFAs, esterified in cell membranes, act as critical signalling molecules in many pathological processes. Currently, agents affecting HUFA metabolism are widely prescribed in diseases involving disordered cell death signalling. However, partly due to rapid metabolism, their role in cell death signalling pathways is poorly characterized. Recently, HUFA-derived mediators, the resolvins/protectins and endocannabinoids, have added opportunities to target selective signals and pathways. This review will focus on the control of cell death by HUFA, eicosanoid (C20 fatty acid metabolites) and docosanoid (C22 metabolites), HUFA-derived lipid mediators, signalling elements in the micro-environment and their potential therapeutic applications. Further therapeutic approaches will involve cell and molecular biology, the multiple hit theory of disease progression and analysis of system plasticity. Advances in the cell biology of eicosanoid and docosanoid metabolism, together with structure/function analysis of HUFA-derived mediators, will be useful in developing therapeutic agents in pathologies characterized by alterations in cell death signalling.
LanguageEnglish
Pages1193-1210
Number of pages18
JournalBritish Journal of Pharmacology
Volume166
Issue number4
Early online date17 May 2012
DOIs
Publication statusPublished - 6 Jun 2012

Fingerprint

Eicosanoids
Unsaturated Fatty Acids
Cell Death
Membranes
Pathologic Processes
Therapeutics
Cell Biology
CD59 Antigens
Therapeutic Human Experimentation
Endocannabinoids
Systems Analysis
Prostaglandins
Disease Progression
Molecular Biology
Signal Transduction
Fatty Acids
Cell Membrane
Pathology
Lipids

Keywords

  • cell death signalling
  • pathophysiology
  • prostaglandins
  • membranes
  • lipids mediators
  • docosanoid
  • therapeutic implications
  • cell death signalling
  • micro-environment
  • eicosanoid
  • metabolism

Cite this

@article{b21ff064cb8f4846b58b01ed5dc24e2a,
title = "Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism",
abstract = "Disruptions of cell death signalling occur in pathological processes, such as cancer and degenerative disease. Increased knowledge of cell death signalling has opened new areas of therapeutic research, and identifying key mediators of cell death has become increasingly important. Early triggering events in cell death may provide potential therapeutic targets, whereas agents affecting later signals may be more palliative in nature. A group of primary mediators are derivatives of the highly unsaturated fatty acids (HUFAs), particularly oxygenated metabolites such as prostaglandins. HUFAs, esterified in cell membranes, act as critical signalling molecules in many pathological processes. Currently, agents affecting HUFA metabolism are widely prescribed in diseases involving disordered cell death signalling. However, partly due to rapid metabolism, their role in cell death signalling pathways is poorly characterized. Recently, HUFA-derived mediators, the resolvins/protectins and endocannabinoids, have added opportunities to target selective signals and pathways. This review will focus on the control of cell death by HUFA, eicosanoid (C20 fatty acid metabolites) and docosanoid (C22 metabolites), HUFA-derived lipid mediators, signalling elements in the micro-environment and their potential therapeutic applications. Further therapeutic approaches will involve cell and molecular biology, the multiple hit theory of disease progression and analysis of system plasticity. Advances in the cell biology of eicosanoid and docosanoid metabolism, together with structure/function analysis of HUFA-derived mediators, will be useful in developing therapeutic agents in pathologies characterized by alterations in cell death signalling.",
keywords = "cell death signalling, pathophysiology, prostaglandins, membranes, lipids mediators, docosanoid, therapeutic implications , cell death signalling , micro-environment, eicosanoid, metabolism",
author = "Jillian Davidson and D Rotondo and Maria Rizzo and Anne Leaver",
year = "2012",
month = "6",
day = "6",
doi = "10.1111/j.1476-5381.2012.01900.x",
language = "English",
volume = "166",
pages = "1193--1210",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
number = "4",

}

Therapeutic implications of disorders of cell death signalling : membranes, micro-environment, and eicosanoid and docosanoid metabolism. / Davidson, Jillian; Rotondo, D; Rizzo, Maria; Leaver, Anne.

In: British Journal of Pharmacology, Vol. 166, No. 4, 06.06.2012, p. 1193-1210.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Therapeutic implications of disorders of cell death signalling

T2 - British Journal of Pharmacology

AU - Davidson, Jillian

AU - Rotondo, D

AU - Rizzo, Maria

AU - Leaver, Anne

PY - 2012/6/6

Y1 - 2012/6/6

N2 - Disruptions of cell death signalling occur in pathological processes, such as cancer and degenerative disease. Increased knowledge of cell death signalling has opened new areas of therapeutic research, and identifying key mediators of cell death has become increasingly important. Early triggering events in cell death may provide potential therapeutic targets, whereas agents affecting later signals may be more palliative in nature. A group of primary mediators are derivatives of the highly unsaturated fatty acids (HUFAs), particularly oxygenated metabolites such as prostaglandins. HUFAs, esterified in cell membranes, act as critical signalling molecules in many pathological processes. Currently, agents affecting HUFA metabolism are widely prescribed in diseases involving disordered cell death signalling. However, partly due to rapid metabolism, their role in cell death signalling pathways is poorly characterized. Recently, HUFA-derived mediators, the resolvins/protectins and endocannabinoids, have added opportunities to target selective signals and pathways. This review will focus on the control of cell death by HUFA, eicosanoid (C20 fatty acid metabolites) and docosanoid (C22 metabolites), HUFA-derived lipid mediators, signalling elements in the micro-environment and their potential therapeutic applications. Further therapeutic approaches will involve cell and molecular biology, the multiple hit theory of disease progression and analysis of system plasticity. Advances in the cell biology of eicosanoid and docosanoid metabolism, together with structure/function analysis of HUFA-derived mediators, will be useful in developing therapeutic agents in pathologies characterized by alterations in cell death signalling.

AB - Disruptions of cell death signalling occur in pathological processes, such as cancer and degenerative disease. Increased knowledge of cell death signalling has opened new areas of therapeutic research, and identifying key mediators of cell death has become increasingly important. Early triggering events in cell death may provide potential therapeutic targets, whereas agents affecting later signals may be more palliative in nature. A group of primary mediators are derivatives of the highly unsaturated fatty acids (HUFAs), particularly oxygenated metabolites such as prostaglandins. HUFAs, esterified in cell membranes, act as critical signalling molecules in many pathological processes. Currently, agents affecting HUFA metabolism are widely prescribed in diseases involving disordered cell death signalling. However, partly due to rapid metabolism, their role in cell death signalling pathways is poorly characterized. Recently, HUFA-derived mediators, the resolvins/protectins and endocannabinoids, have added opportunities to target selective signals and pathways. This review will focus on the control of cell death by HUFA, eicosanoid (C20 fatty acid metabolites) and docosanoid (C22 metabolites), HUFA-derived lipid mediators, signalling elements in the micro-environment and their potential therapeutic applications. Further therapeutic approaches will involve cell and molecular biology, the multiple hit theory of disease progression and analysis of system plasticity. Advances in the cell biology of eicosanoid and docosanoid metabolism, together with structure/function analysis of HUFA-derived mediators, will be useful in developing therapeutic agents in pathologies characterized by alterations in cell death signalling.

KW - cell death signalling

KW - pathophysiology

KW - prostaglandins

KW - membranes

KW - lipids mediators

KW - docosanoid

KW - therapeutic implications

KW - cell death signalling

KW - micro-environment

KW - eicosanoid

KW - metabolism

UR - http://www.scopus.com/inward/record.url?scp=84861306248&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2012.01900.x

DO - 10.1111/j.1476-5381.2012.01900.x

M3 - Literature review

VL - 166

SP - 1193

EP - 1210

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -